Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the Caveolin-1 (P132L) mutation

Cell Cycle

Volumn 8, Issue 9, 2009, Pages 1396-1401

  Mercier, Isabelle ^a,b   Bryant, Kelly G ^a,b   Sotgia, Federica ^a,b   Bonuccelli, Gloria ^a,b   Witkiewicz, Agnieszka K ^c   Dasgupta, Abhijit ^d   Jasmin, Jean François ^a,b   Pestell, Richard G ^a,b   Lisanti, Michael P ^a,b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Breast cancer; Caveolin 1; Immunostaining patterns; P132L mutation

Indexed keywords

CAVEOLIN 1;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER PATIENT; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DNA SEQUENCE; ENDOPLASMIC RETICULUM; GENE MUTATION; GOLGI COMPLEX; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MUTATIONAL ANALYSIS; PATIENT CODING; PREDICTION; SCREENING; STAINING; TISSUE DIFFERENTIATION;

EID: 65949098884     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.9.8307     Document Type: Article

References (26)

1. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998; 17:6633-6648
2. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 1997; 272:16374-16381 (Pubitemid 27276462)
3. Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002; 21:2365-2375 (Pubitemid 34413560)
4. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276:38121-38138
5. Williams TM, Lee H, Cheung MW, Cohen AW, Razani B, Iyengar P, et al. Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogeneinduced tumorigenesis. J Biol Chem 2004; 279:24745-24756
6. Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Allen KG, et al. Human breast cancer-associated fibroblasts (CAFs) show Caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther 2008; 7:1212-1225
7. Li T, Sotgia F, Vuolo MA, Li M, Yang WC, Pestell RG, et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 2006; 168:1998-2013.
8. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 2001; 61:2361-2364
9. Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 2002; 161:1357-1369
10. Liedtke C, Kersting C, Burger H, Kiesel L, Wulfing P. Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol 2007; 5:110. (Pubitemid 350167996)
11. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical and in situ hybridization analysis. Clin Cancer Res 2007; 13:90-101.
12. Sotgia F, Williams TM, Schubert W, Medina F, Minetti C, Pestell RG, et al. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol 2006; 168:292-309. (Pubitemid 43062581)
13. Williams TM, Cheung MW, Park DS, Razani B, Cohen AW, Muller WJ, et al. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 2003; 14:1027-1042
14. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 1999; 59:5719-5723
15. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002; 87:1140-1144 (Pubitemid 35418110)
16. Campbell L, Gumbleton M, Griffiths DF. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 2003; 89:1909-1913. (Pubitemid 37533269)
17. Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, et al. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 2003; 42:195-202.
18. Chen ST, Lin SY, Yeh KT, Kuo SJ, Chan WL, Chu YP, et al. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers. Int J Mol Med 2004; 14:577-582
19. Park SS, Kim JE, Kim YA, Kim YC, Kim SW. Caveolin-1 is downregulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology 2005; 47:625-630 (Pubitemid 41775186)
20. Pinilla SM, Honrado E, Hardisson D, Benitez J, Palacios J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006; 99:85-90. (Pubitemid 44168607)
21. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, et al. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 2006; 95:219-228
22. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998; 4:1873-1880. (Pubitemid 28369170)
23. Dix B, Robbins P, Carrello S, House A, Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 1994; 70:585-590 (Pubitemid 24305581)
24. Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S, Hirohashi S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992; 83:978-984
25. Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, et al. Genetic ablation of Caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol 2009; 174:1172-1190
26. Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, Griffith OL, et al. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 2008; 68:8210-8220